ReviewNature reviews. Urology2020
Extracellular vesicles in urological malignancies: an update.
Review in Nature reviews. Urology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 59 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 1 synthesis or guideline pooled it, 109 citations in OpenAlex.
- Extracellular Vesicles: A New Source of Biomarkers in Pediatric Solid Tumors? A Systematic Review.Frontiers in oncology · 2022Pooled it
- Trial
- Tumor-associated macrophages and lineage plasticity in prostate cancer: from established myeloid programs to emerging spatial hypotheses.Frontiers in immunology · 2026Review
- Bridging laboratory innovation to translational research and commercialization of extracellular vesicle isolation and detection.Biosensors & bioelectronics · 2025Review
- Roadblocks of Urinary EV Biomarkers: Moving Toward the Clinic.Journal of extracellular vesicles · 2025Review
- Non-coding transcriptome profiles in clear-cell renal cell carcinoma.Nature reviews. Urology · 2025Review
- Potential role of exosomes derived from the tumor microenvironment in tumor progression and treatment.Frontiers in oncology · 2025Review
- Extracellular vesicle-derived microRNAs in renal cell carcinoma: biological roles and clinical applications.Frontiers in cell and developmental biology · 2025Review
- Androgen Receptor and Non-Coding RNAs' Interaction in Renal Cell Carcinoma.Non-coding RNA · 2024Review
- Extracellular Vesicle Preparation and Analysis: A State-of-the-Art Review.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Review
- Article
- Tumor promoting effect of spheroids in an orthotopic prostate cancer mouse model.Scientific reports · 2024Article
- Diagnostic liquid biopsy biomarkers in renal cell cancer.Nature reviews. Urology · 2024Review
- Targeting cancer-derived extracellular vesicles by combining CD147 inhibition with tissue factor pathway inhibitor for the management of urothelial cancer cells.Cell communication and signaling : CCS · 2024Article
- Unraveling the Connection: Extracellular Vesicles and Non-Small Cell Lung Cancer.International journal of nanomedicine · 2024Review
- Recent Developments and Application of Mass Spectrometry Imaging in N-Glycosylation Studies: An Overview.Mass spectrometry (Tokyo, Japan) · 2024Review
- Prostate-derived circulating microRNAs add prognostic value to prostate cancer risk calculators.Journal of extracellular biology · 2023Article
- Current knowledge on the role of extracellular vesicles in endometrial receptivity.European journal of medical research · 2023Review
- Protein Biomarker Discovery Studies on Urinary sEV Fractions Separated with UF-SEC for the First Diagnosis and Detection of Recurrence in Bladder Cancer Patients.Biomolecules · 2023Article
- 3D-CEUS tracking of injectable chemo-sonodynamic therapy-enabled mop-up of residual renal cell carcinoma after thermal ablation.Materials today. Bio · 2023Article
Corrections and comments
- Erratum issued
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extracellular vesicles (EVs) have an essential functional role in local tumour progression, metastatic spread and the emergence of drug resistance in bladder, kidney and prostate cancer. Thus, EVs could be diagnostic, prognostic and predictive biomarkers for these malignancies. Virtually all biomolecules (including DNA, mRNA, microRNA, long non-coding RNA, proteins and lipids) packaged into EVs have been tested as biomarkers in blood and urine samples. The results are very heterogeneous, but promising biomarker candidates have been identified. Differing methods of EV isolation, characterization and analysis of their content have been used owing to a lack of international consensus; hence, comparing study results is challenging. Furthermore, validation of potential biomarkers in independent cohorts or prospective trials has rarely been performed. Future efforts to establish EV-derived biomarkers need to adequately address these points. In addition, emerging technologies such as mass spectroscopy and chip-based approaches can identify surface markers specific for cancer-associated EVs and will enable specific separation from blood and urine EVs, which probably will improve their performance as biomarkers. Moreover, EVs could be harnessed as therapeutic drug delivery vehicles for precise and effective anticancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.